| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 10 | +60.00% | -0.75% | -0.10% | -0.66% | -0.58% | — |
| 14d | 10 | +60.00% | -0.10% | +0.15% | -0.24% | -1.87% | — |
| 30d | 10 | +60.00% | -2.55% | -1.27% | -1.28% | -4.42% | — |
| 60d | 10 | +40.00% | -1.34% | -5.36% | +4.02% | +11.78% | — |
| 90d | 10 | +40.00% | -4.94% | +1.10% | -6.04% | -1.01% | — |
| 180d | 10(4 pending) | +33.33% | +73.31% | +6.57% | +66.74% | +79.25% | — |
| 1y | 10(5 pending) | +20.00% | +97.83% | +15.40% | +82.43% | +149.77% | — |
| 2y | 10(9 pending) | +0.00% | +53.27% | +42.90% | +10.36% | +10.36% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 18,652 | $2.36 | $44.0K | 742,506 | Feb 6, 2026 | Feb 9, 2026 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 3,471 | $2.24 | $7.8K | 761,158 | Feb 4, 2026 | Feb 4, 2026 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 24,224 | $2.14 | $51.8K | 764,629 | Feb 3, 2026 | Feb 4, 2026 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 18,891 | $2.20 | $41.6K | 788,853 | Feb 2, 2026 | Feb 4, 2026 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 68,000 | — | — | 807,744 | Feb 2, 2026 | Feb 4, 2026 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 137,000 | — | — | 137,000 | Feb 2, 2026 | Feb 4, 2026 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 1,695 | $1.97 | $3.3K | 739,744 | Aug 28, 2025 | Sep 2, 2025 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 24,920 | $0.78 | $19.4K | 741,439 | Feb 5, 2025 | Feb 5, 2025 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 27,643 | $0.78 | $21.6K | 766,359 | Feb 5, 2025 | Feb 5, 2025 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 3,974 | $0.78 | $3.1K | 794,002 | Feb 5, 2025 | Feb 5, 2025 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 266,139 | — | — | 797,976 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,213 | $1.35 | $3.0K | 531,837 | Aug 27, 2024 | Aug 29, 2024 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 30,971 | $1.36 | $42.1K | 534,050 | Feb 2, 2024 | Feb 5, 2024 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 239,731 | — | — | 565,021 | Feb 1, 2024 | Feb 5, 2024 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Development Officer | 1,854 | $1.26 | $2.3K | 325,290 | Aug 28, 2023 | Aug 30, 2023 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | SALE Chief Operating Officer | 3,394 | $1.86 | $6.3K | 327,144 | Feb 2, 2023 | Feb 3, 2023 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 265,957 | — | — | 330,538 | Feb 1, 2023 | Feb 3, 2023 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 53,190 | — | — | 53,190 | Feb 1, 2022 | Feb 3, 2022 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 38,014 | — | — | 64,581 | Feb 1, 2022 | Feb 3, 2022 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 24,067 | — | — | 26,567 | Aug 26, 2021 | Aug 30, 2021 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 57,432 | — | — | 57,432 | Feb 1, 2021 | Feb 3, 2021 ↗ | View → |
| SPRO SPERO THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 55,000 | — | — | 55,000 | Feb 3, 2020 | Feb 3, 2020 ↗ | View → |